Real-world evidence for the efficacy and safety of risankizumab in moderate-to-severe psoriasis: a systematic review and meta-analysis

These data is a supplementary data for a manuscript entitled " Real-world evidence for the efficacy and safety of risankizumab in moderate-to-severe psoriasis: a systematic review and meta-analysis ". In this study, we showed that risankizumab seemed to be an advantageous treatment option for moderate-to-severe psoriasis with its satisfactory performance in efficacy, safety and drug discontinuation in long term based on real-world evidence. Owing to the current limited number and quality of studies, more long-term and high-quality real-world studies are required for a more comprehensive assessment of risankizumab.